Comprehensive ReviewEpidemiology of Febrile Neutropenia
References (79)
- et al.
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
Ann Oncol
(2003) - et al.
Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies
J Infect
(2001) - et al.
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial
Clin Breast Cancer
(2002) - et al.
The economics of febrile neutropenia: implications for the use of colony-stimulating factors
Eur J Cancer
(1998) - et al.
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis
Am J Med
(2002) - et al.
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
Eur J Cancer
(1993) - et al.
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial
Blood
(1992) - et al.
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
Blood
(1997) - et al.
Randomized, doubleblind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas
Blood
(1993) - et al.
Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia
Am J Med
(1996)
Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever
Eur J Cancer
(1990)
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Clin Infect Dis
(2002)
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
Ann Intern Med
(1966)
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
J Clin Oncol
(2002)
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B
J Natl Cancer Inst
(1998)
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials
J Natl Compr Cancer Network
(2003)
Dose-dense anthracyclinebased chemotherapy for node-positive breast cancer
J Clin Oncol
(2002)
Incidence and predictors of low dose intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices
J Clin Oncol
(2003)
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
Leuk Lymphoma
(2003)
Risk and timing of hospitalization for febrile neutropenia among patients receiving CHOP-like regimens for intermediate-grade non-Hodgkin's lymphoma
Cancer
(2003)
Risk models for the prediction of chemotherapy-induced neutropenia
Neutropenia Oncol
(2001)
First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy
J Clin Oncol
(1998)
Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer
J Clin Oncol
(1998)
Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule
J Clin Oncol
(1992)
Colony-stimulating factors may reduce complications and death in solid tumor patients with fever and neutropenia
Proc Am Soc Clin Oncol
(2000)
Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia
Eur J Clin Microbiol Infect Dis
(1999)
Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients
Intensive Care Med
(2002)
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials
Clin Infect Dis
(1997)
Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome
Arch Intern Med
(1998)
Cost-effectiveness of myeloid growth factors in cancer chemotherapy
Curr Hematol Rep
(2003)
Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party
J Clin Oncol
(2000)
Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
J Clin Oncol
(2003)
A predictive model for neutropenia associated with cancer chemotherapy
Pharmacotherapy
(2000)
Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model
Cancer
(2003)
Risk models for neutropenic complications associated with breast cancer adjuvant chemotherapy
Proc Am Soc Clin Oncol
(2002)
The risks and consequences of chemotherapy-induced neutropenia
Cancer
(2003)
Risk assessment in oncology practice: from risk factors to risk models
Oncology
(2003)
Incorporation of quality of life considerations into decision models for the use of colony stimulating factors in chemotherapy patients at risk for febrile neutropenia
Decline in absolute neutrophil count (ANC) is associated with lower quality of life (QOL) in cancer patients receiving docetaxel
Proc Am Soc Clin Oncol
(2002)
Cited by (0)
Copyright © 2003 Elsevier. Published by Elsevier Inc. All rights reserved.